This column last specifically reviewed the topic of metformin benefit on cancer reduction two months ago. We know that stress and bad diet -dysnutrition and lack of exercise – promote the   risks of fatigue, insulin resistance, lipidemia, diabetes, obesity, cancer, infection..

To put diabetes in perspective, we need to read the classic articles by

A J Hodgson of 1912 of his experience with diabetes over 20 years  in Canada, in which he posed as the “chief cause in the growing  epidemic of diabetes that past half century the rapid increase of intake of glucose or ‘corn syrup’, the astounding amounts being eaten at speed; and the nervous  stress and strain of American life”.  Nothing seems to have changed in the endless Western preference for exposure to stress and  lunatic  gluttony;  and  lunatic Regulatory  blindness the past century in doing nothing to enforce improvement in the food chain, while  cigarette smoking and cannabis have been drastically regulated. So much of what Hodgson wrote about the chief cause of epidemic ie type 2 diabetes remains true today- personal hygiene, the unwillingness to eat and exercise  sensibly;

 and by

Banting  Macleod  Best & Collip (  Toronto 1921) on the first extraction and use of  insulin,

and by

Werner and Bell (Dublin 1922)   on the first synthesis of dimethylguanidine- metformin.


*The Finnish ATBC study 2006 showed that the worst obesity and metabolic syndrome associated with 40% increase in bowel especially rectal cancer.

*In older obese women in Italy 1999, type 2 diabetes tripled the incidence of endometrial cancer.

*In a 10year study in Jena, Germany (2005), insulin-treated diabetics  showed a 10 fold increase in cancer (mostly rectum and colon)  compared to the control population.

*In a study of pancreas cancer in Italy 2004, pancreas cancer was three times more common in those with type 2 DM than in non-diabetics.

*We have previously reviewed the evidence that lowering lipidemia – hypolipidemia– with statins may increase cancer risk, without reducing insulin resistance or diabetes risk.

A new trial from the Univ Connecticut last month , and two new reviews last week- from the European Institute of Oncology and the University California,  strengthen the case that meformin is a crucial cancer preventive and therapy, that by promoting AMPK at the cellular level, it switches off cancer cell proliferation ie immortality, while promoting anti-aging in all healthy tissues.

METHODS: Pubmed and Google search for English  abstracts under “metformin AND CANCER”


There are now at least 12  studies and trials of metformin and cancer available on Pubmed and through the internet;

too disparate  to do a metanalysis, but certainly a review offering nothing but good news:

Metformin has been reported in studies to produce less cancers and cancer-related deaths than occur without it ie with insulin or sulphonylureas or without any antidiabetic drugs:

metformin and cancers in human :

* 29% fewer cancer deaths (non significant) in diabetics after mean 13.6yrs –UKPDS 1998;

* reverse endometrial hyperplasia in a woman-  2003 Mayo clinic ;

*perhaps 21% fewer cancers in diabetics on metformin Tayside UK 2005

*25% less cancers in human diabetics than those treated with other antidiabetics  Canada 2006;
* Increases Pathologic Complete Response Rates in Breast Cancer Patients With Diabetes Univ Texas 2008.

*metformin benefit on cancer in human cancer cell cultures:

Prostate cancer in vitro  France 2008

lung cancer in vitro Univ Arizona 2005;

breast cancer in vitro -McGill, Canada 2006, and Univ Connecticut 2009;

colon cancer in vitro Pennsylvania 2007;

ovarian cancer McGill 2008;

and in hamsters: pancreas cancer Nebraska 2001;

and in mice lung cancer McGill 2008 ..

YET USA Industry and regulators – owing to obvious commercial vested interests- take the indefensible stance that eg human estriol is an unregistered new drug that must be proven in trials. It is said that no new drug can be registered there before an average of $600million has been spent on research and trials. So no sane for-profit company is going to fund trials on an unpatentible natural molecule – especially a sex hormone that has evolved in humans for millions of years , without a single reported case of natural or use-related adversity.

The same goes for metformin- a natural plant derivative first isolated 87 years ago, the only drug ever tested in a 20year RCT- and proven in numerous trials and controlled studies to have zero serious adverse effects, and proven to be a panacea- the only drug effective against virtually every major chronic degenerative disease of aging.

Yet threatening regulatory concern is hypocritically expressed – without the slightest evidence against it – when metformin  is used as the only evidence-based drug to prevent and reverse the epidemic complications of overweight BEFORE obesity, PCOS, hypertension, arthritis, diabetes, CVD, stroke, visual / renal impairment, neuropathy, or cancer present.


It is well shown in studies that waiting for obesity let alone diabetes increases major disease let alone premature death by 2 to 5 fold; and that used in prevention it reduces the incidence of new diabetes by 30% to 90% in a dose-dependent fashion up to reasonable dose tolerance; and in type 2 diabetes halves the incidence of premature death.

So since  metformin is  associated with reduction of even cancer, it should (except in terminal or wasted non-diabetic patients, or temporarily in unstable renal or respiratory-metabolic function)  be added cautiously and titrated up to moderate dose short of intolerance in any patient presenting at any age after 12yrs if not younger with rising overweight ie BMI much > 25kg/sqm or waist girth much >80cm, unresponsive to diet and lifestyle attempts

Dedicated  to    (mal)nutrition- metabolic syndrome – PCOS – diabetes – cancer and metformin  sufferers, and researchers:  Werner and Bell (Dublin);   Sirs Harold  Himsworth and   Stanley Davidson (UK);  Professors  Jack Brock, Stewart Truswell and WPU Jackson at University of Cape Town UCT; Frank Maudsley Parsons (Univ Leeds); Rick Turner and Rury Holman(UKPDS); Gilbert Forbes, Tim Lohman, Gerald  Reaven, Fred Naftolin, Charles Glueck (USA); and the DPPRG trialists on all continents.




Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s